TransThera Sciences (Nanjing), Inc. (Stock Code: 2617) announced the completion of a placing of 2,100,000 new H shares under its general mandate. Placing shares were priced at HK$92.85 each, generating gross proceeds of about HK$194.99 million and net proceeds of around HK$190.14 million. According to the announcement, these new shares account for approximately 0.70% of the existing issued H share capital prior to completion and around 0.53% of total issued shares at that time.

The company stated that it plans to allocate about 60% of the proceeds to clinical trial and development expenses for its Core Product, Tinengotinib, 30% to the research and development of other products, and 10% to working capital and general corporate purposes. Following the placement, total issued shares of TransThera Sciences (Nanjing), Inc. increased from 396,897,633 to 398,997,633.